Pilot Study AHSP as a Biomarker of Sickle Cell Disease in a Population of Adults and Children

Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Evaluation of AHSP concentration in total blood as a biomarker in adult and pediatric sickle cell patients

Eligibility
Participation Requirements
Sex: All
Minimum Age: 3
Healthy Volunteers: f
View:

⁃ Adults: \> 15 years and 6 months

⁃ Pediatrics: ≥ 3 years and ≤ 15 years and 6 months

⁃ Known SS or Sβ0 phenotypes

‣ 1 -Adults: \> 15 years and 6 months /Pediatrics: ≥ 3 years and ≤ 15 years and 6 months 2-Absence of Hemoglobinopathy 3-Follow-up for one of the following conditions (adults): Evaluation of hematological disease excluding hemoglobinopathy, evaluation of prolonged fever or inflammatory syndrome, initial or episodic evaluation of an auto-inflammatory disease or systemic disease, general health deterioration

• Follow-up for one of the following conditions (pediatrics): Suspected precocious puberty, growth delay, or neurodevelopmental disorder

‣ 4-Blood sample planned as part of medical care

Locations
Other Locations
France
Centre Hospitalier de Saint-Denis
RECRUITING
Saint-denis
Contact Information
Primary
Stéphanie NGO, Coordinating Investigator
stephanie.ngo@ch-stdenis.fr
stephanie.ngo@ch-stdenis.fr
Backup
Stéhanie COSSEC, Project Coordinator
stephanie.cossec@ghtpdfr.fr
stephanie.cossec@ghtpdfr.fr
Time Frame
Start Date: 2025-03-06
Estimated Completion Date: 2027-01-20
Participants
Target number of participants: 100
Treatments
Experimental: sickle cell patients over 15 and a half years old
sickle cell patients over 15 and a half years old with SS or Sβ0 phenotype
Other: control patients over 15 and a half years old
control patients over 15 and a half years old without hemoglobin abnormalities, recruited at the hospital
Experimental: pediatric sickle cell patients (aged between 3 and 15 and a half years)
pediatric sickle cell patients (aged between 3 and 15 and a half years) with SS or Sβ0 phenotype
Other: pediatric control patients (aged between 3 and 15 and a half years)
pediatric control patients (aged between 3 and 15 and a half years) without hemoglobin abnormalities, recruited at the hospital
Sponsors
Leads: Centre Hospitalier de Saint-Denis
Collaborators: Inserm U955

This content was sourced from clinicaltrials.gov